Novavax CCO Silvia Taylor discusses the company’s role in developing a Covid vaccine, the ensuing vaccine controversy, and how Novavax refined its strategy and its positioning. Throughout those challenges, the corporate affairs function has managed multiple stakeholder relationships, with an emphasis on adding commercial value.